Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Outline of Final Research Achievements |
In order to validate a potential of CD271 as a squamous cell carcinoma target, CD271 was knock-downed by shRNA. CD271 inhibition inhibited both cell proliferation and migration. p42/44Erk inhibition as well as RhoA inhibition inhibited malignant phenotypes of HPCM2 cells. On the other hand, an anti-CD271 Ab did not show significant in vitro effect on the same cells. Together, CD271 is shown to be a potential target for squamous cell carcinoma therapy.
|